Literature DB >> 1728999

Imaging of the hip joint. Computed tomography versus magnetic resonance imaging.

P Lang1, H K Genant, H E Jergesen, W R Murray.   

Abstract

The authors reviewed the applications and limitations of computed tomography (CT) and magnetic resonance (MR) imaging in the assessment of the most common hip disorders. Magnetic resonance imaging is the most sensitive technique in detecting osteonecrosis of the femoral head. Magnetic resonance reflects the histologic changes associated with osteonecrosis very well, which may ultimately help to improve staging. Computed tomography can more accurately identify subchondral fractures than MR imaging and thus remains important for staging. In congenital dysplasia of the hip, the position of the nonossified femoral head in children less than six months of age can only be inferred by indirect signs on CT. Magnetic resonance imaging demonstrates the cartilaginous femoral head directly without ionizing radiation. Computed tomography remains the imaging modality of choice for evaluating fractures of the hip joint. In some patients, MR imaging demonstrates the fracture even when it is not apparent on radiography. In neoplasm, CT provides better assessment of calcification, ossification, and periosteal reaction than MR imaging. Magnetic resonance imaging, however, represents the most accurate imaging modality for evaluating intramedullary and soft-tissue extent of the tumor and identifying involvement of neurovascular bundles. Magnetic resonance imaging can also be used to monitor response to chemotherapy. In osteoarthrosis and rheumatoid arthritis of the hip, both CT and MR provide more detailed assessment of the severity of disease than conventional radiography because of their tomographic nature. Magnetic resonance imaging is unique in evaluating cartilage degeneration and loss, and in demonstrating soft-tissue alterations such as inflammatory synovial proliferation.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; Non-NASA Center

Mesh:

Year:  1992        PMID: 1728999

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  7 in total

1.  Imaging evaluation of patients with osteonecrosis of the femoral head.

Authors:  Todd P Pierce; Julio J Jauregui; Jeffrey J Cherian; Randa K Elmallah; Michael A Mont
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

2.  How do acetabular version and femoral head coverage change with skeletal maturity?

Authors:  Andreas M Hingsammer; Sarah Bixby; David Zurakowski; Yi-Meng Yen; Young-Jo Kim
Journal:  Clin Orthop Relat Res       Date:  2015-04       Impact factor: 4.176

3.  Diagnostic performance of MR imaging in the assessment of subchondral fractures in avascular necrosis of the femoral head.

Authors:  Lee-Ren Yeh; Clement K H Chen; Yi-Luan Huang; Huay-Ben Pan; Chien-Fang Yang
Journal:  Skeletal Radiol       Date:  2009-02-21       Impact factor: 2.199

Review 4.  The role of imaging in diagnosis and management of femoral head avascular necrosis.

Authors:  Guglielmo Manenti; Simone Altobelli; Luca Pugliese; Umberto Tarantino
Journal:  Clin Cases Miner Bone Metab       Date:  2016-04-07

5.  Magnetic resonance imaging in osteoarthrosis of the dysplastic hip.

Authors:  Y Hasegawa; H Fukatsu; T Matsuda; T Iwase; H Iwata
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

6.  Temporomandibular Joint Space Dimensions among Saudi Patients with Temporomandibular Disorders: MRI-Based Retrospective Study.

Authors:  Nasser Raqe Alqhtani; Malak Sultan Alkhaldi; Alhanoof Falah Alanazi; Abdullatif Saad Alabdulsalam; Adel Alenazi; Mahmud Uz Zaman; Adel Alzahrani; Ahmad Alshadwi; Ali Al Rafedah; Mohammed AlOtaibi
Journal:  Int J Clin Pract       Date:  2022-08-02       Impact factor: 3.149

7.  An MRI-based technique for assessment of lower extremity deformities-reproducibility, accuracy, and clinical application.

Authors:  Stefan Hinterwimmer; Heiko Graichen; Thomas J Vogl; Nasreddin Abolmaali
Journal:  Eur Radiol       Date:  2008-03-20       Impact factor: 7.034

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.